ReviewDiabetes technology & therapeutics2017
Continuous Glucose Monitoring and Global Reimbursement: An Update.
Review in Diabetes technology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Equity of Continuous Glucose Monitoring in Children and Young People With Type 1 Diabetes: A Systematic Review.Pediatric diabetes · 2025Pooled it
- Patient experiences of continuous glucose monitoring and sensor-augmented insulin pump therapy for diabetes: A systematic review of qualitative studies.Journal of diabetes · 2023Pooled it
- Pooled it
- A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care.Frontiers in endocrinology · 2021Pooled it
- AI-Ready Multimodal Wearable Biosensors Beyond Glucose: Biofluid Sampling, Sensor Fusion, and Clinical Translation.Biosensors · 2026Review
- Recent advances and ongoing challenges in diabetes prevention and control in China.Innovation (Cambridge (Mass.)) · 2026Review
- Life stage transitions for people with type 1 diabetes.The lancet. Diabetes & endocrinology · 2025Review
- Trends and Disparities in Technology Use and Glycemic Control in Type 1 Diabetes.JAMA network open · 2025Article
- The Relationship Between Glycated Albumin and Time in Tight Range in Type 2 Diabetes.Journal of diabetes · 2025Article
- The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands.Journal of clinical & translational endocrinology · 2024Article
- Glycated Albumin Correlates With Time-in-Range Better Than HbA1c or Fructosamine.The Journal of clinical endocrinology and metabolism · 2023Article
- Inequity in access to continuous glucose monitoring and health outcomes in paediatric diabetes, a case for national continuous glucose monitoring funding: A cross-sectional population study of children with type 1 diabetes in New Zealand.The Lancet regional health. Western Pacific · 2023Article
- Socioeconomic status and diabetes technology use in youth with type 1 diabetes: a comparison of two funding models.Frontiers in endocrinology · 2023Article
- Healthcare Utilization, Costs, and Adverse Events of Real-Time Continuous Glucose Monitoring versus Traditional Blood Glucose Monitoring Among US Adults with Type 1 Diabetes.Journal of diabetes science and technology · 2022Article
- Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia.Diabetic medicine : a journal of the British Diabetic Association · 2022Article
- Article
- Use of Continuous Glucose Monitoring in the Assessment and Management of Patients With Diabetes and Chronic Kidney Disease.Frontiers in endocrinology · 2022Review
- Overcoming Barriers to Diabetes Technology in Youth with Type 1 Diabetes and Public Insurance: Cases and Call to Action.Case reports in endocrinology · 2022Article
- Effect of Insulin Pump Use on Diabetic Ketoacidosis in Type 1 Diabetes Mellitus: A Matched Cohort Study.Journal of clinical medicine · 2021Article
- Benefits and Drawbacks of Continuous Glucose Monitoring (CGM) Use in Young Children With Type 1 Diabetes: A Qualitative Study From a Country Where the CGM Is Not Reimbursed.Journal of patient experience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Real-time continuous glucose monitoring has been available for a decade and reimbursement for the technology has been slowly growing. Reasons for the various rates of reimbursement and adoption are explored in this article and the status of country-wide reimbursement is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.